Medically integrated dispensing is well-positioned to support value-based oncology care models and closer patient follow-up and monitoring, says Katherine Tobon, PharmD, BCOP.
Katherine Tobon, PharmD, BCOP
Advertisement
Katherine Tobon, PharmD, BCOP, is an advanced clinical pharmacy specialist in malignant hematology at Moffitt Cancer Center in Tampa, Florida.
Articles by Katherine Tobon, PharmD, BCOP
Medically integrated dispensing (MID) improves monitoring and supports value-based care, but startup costs and payer barriers remain, notes Katherine Tobon, PharmD, BCOP.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5